Reduced Gastrointestinal Toxicity Following Inhibition of the Biliary Excretion of Irinotecan and Its Metabolites by Probenecid in Rats
- 1 January 2002
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 19 (9) , 1345-1353
- https://doi.org/10.1023/a:1020358910490
Abstract
Purpose. To ameliorate the late-onset of severe gastrointestinal toxicity provoked by irinotecan (CPT-11), which may be related to the biliary excretion of CPT-11 and/or its metabolites. Methods....Keywords
This publication has 28 references indexed in Scilit:
- In vitro activation of irinotecan to SN-38 by human liver and intestine.1999
- Expression of the MRP2 Gene-Encoded Conjugate Export Pump in Human Kidney Proximal Tubules and in Renal Cell CarcinomaJournal of the American Society of Nephrology, 1999
- Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.1997
- Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with CisplatinJapanese Journal of Cancer Research, 1995
- ATP-dependent Efflux of 2,4-Dinitrophenyl-S-glutathioneJournal of Biological Chemistry, 1995
- Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urineCancer Chemotherapy and Pharmacology, 1995
- Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.Folia Pharmacologica Japonica, 1995
- Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1991
- NONLINEAR PHARMACOKINETICS OF CPT-11 IN RATS1990
- Non-linear elimination and protein binding of probenecidEuropean Journal of Clinical Pharmacology, 1987